Tags : Glenmark

PharmaShots Weekly Snapshot (September 16– 20, 2019)

1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients Published: Sept 20, 2019 | Tags: Astellas, FibroGen, […]Read More

Top 20 Generics Pharma Companies Based On 2018 Revenue

The global generics pharmaceutical market is continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs, are always needed in the market. Generics are approved copies of small molecule drugs which contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of […]Read More

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary Hyperoxaluria 2.Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program Published: Aug 22, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology […]Read More

Glenmark’s Combination Therapy of Remogliflozin Etabonate + Metformin Hydrochloride Receive

Shots: Glenmark has received the regulatory approval to commercialize the combination therapy of remogliflozin etabonate (100mg) + metformin hydrochloride (500/1000mg) as an adjunct to diet and exercise to improve glycemic control in T2D Mellitus patients in India under the brand names ‘Remo-M’ and Remozen-M’ In Apr’2019, Glenmark has received approval of remogliflozin (100mg, bid) based […]Read More

Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize

Shots: Glenmark to receive up front, license fee and royalties on sales and is responsible to manufacture and supply Remogliflozin. Torrent to get rights to commercialize Remogliflozin under the trademark Zucator in India In Apr’2019, Remogliflozin has received CDSCO’s approval following the completion of its P-III studies assessing Remogliflozin vs Dapagliflozin for the treatment of […]Read More

Novartis to Collaborate with Glenmark to Promote, Commercialize and Distribute

Shots: Novartis signs an exclusive commercialization agreement with Glenmark to commercialize three respiratory therapies i.e, Seebri, Onbrize and Ultibro for treating COPD in Brazil. Novartis will be responsible for the manufacturing of therapies The focus of the collaboration is to bolster Glenmark’s respiratory franchise and to expand its respiratory portfolio in Brazil. The agreement will […]Read More

Yuhan Signs an Exclusive License Agreement with Glenmark for its

Shots: Glenmark to receive upfront, milestones and royalties on sales from Yuhan. Yuhan to get exclusive commercialization rights for Glenmark’s Ryaltris in South Korea Yuhan will be responsible for its regulatory approval and Glenmark to take care of manufacturing and supply of Ryaltris in South Korea Ryaltrisis a FD combination of anti-histamine and steroid i.e […]Read More